24/7 Market News Snapshot 27 June, 2025 – Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX)

June 27, 2025

DENVER, Colo., 27 June, 2025 (www.247marketnews.com) – (NASDAQ:AMIX) are discussed in this article.
Autonomix Medical, Inc. (AMIX) is experiencing a positive surge in pre-market trading with shares priced at $1.273, marking a notable increase of approximately 1.84% from the previous close of $1.250. The trading volume has reached 2.49 million shares, highlighting strong investor interest and indicating potential upward momentum. Observations of key technical indicators, including moving averages and momentum oscillators, suggest that further price appreciation may be feasible if this positive trend continues. Investors are advised to keep an eye on resistance levels around $1.30, as surpassing this threshold could reinforce an ongoing bullish trajectory. Overall, AMIX emerges as a compelling opportunity within the current market landscape.

In a significant development, Autonomix Medical has announced the issuance of U.S. Patent No. 12,279,889 B2, which strengthens the company’s innovative stance in the realm of nerve-targeted treatments. This patent underscores Autonomix’s commitment to advancing minimally invasive solutions aimed at addressing critical medical conditions, positioning the company favorably in the multi-billion-dollar market for nerve-focused therapeutics.

The ‘889 patent encompasses pioneering systems and methodologies designed for the precise localization, monitoring, and mapping of electrophysiological signals pertinent to neuromodulation and denervation procedures. This technology is particularly relevant for therapies targeting sympathetic nerve activity, including renal denervation for hypertension and chronic pain management.

CEO Brad Hauser expressed optimism regarding this patent as a milestone in the company’s mission to provide more effective, less invasive treatment options for nerve-related disorders. The novel technology includes sensors embedded in microneedles and advanced control systems poised to transform chronic pain management and offer alternatives to more invasive treatments.

As Autonomix prepares to submit an Investigational Device Exemption (IDE) and plans for U.S. clinical trials in 2025, it aims to assess the effectiveness of its Autonomix Sensing and RF Ablation System for alleviating pancreatic cancer pain, a condition currently lacking in effective management solutions. With a robust portfolio of over 80 patents, Autonomix Medical is at the forefront of revolutionizing care for nerve-related disorders.

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.